BML-257 is an potent inhibitor of AKT1 translocation and has been observed to attenuate cannabinoid agonist-simulated neurosphere proliferation. AKT1 is a gene of the AKT family that encode for serine/threonine kinases. AKT1 is associated with pathways of cellular survival and has been implicated as a factor of various cancers. This product is often utilized in experiments concerning phosphoinostitide-3 kinase signaling and the PI3/AKT pathway. BML-257 also inhibits HCV (hepatitis C virus) NS5B RNA-dependent RNA polymerase (RdRp) with an IC50 value of 79 μM.
1. Lundholt, B.K., et al. 2005. J Biomol Screen. 10: 20-29. PMID: 15695340
2. Molina-Holgado, F., et al. 2007. Eur. J. Neurosci. 25: 629-634. PMID: 17328768
See how others have used BML-257 (CAS 32387-96-5). Click on the entry to view the PubMed entry .
PMID: # 30816566 Lee, SI.|Roney, MSI.|Park, JH.|Baek, JY.|Park, J.|Kim, SK.|Park, SK.| et al. 2019. Prostate. 79: 720-731.
PMID: # 25786691 Dong, G. et al. 2015. J. Immunol. 194: 3745-55.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.